Genetic variation in IL28B (IFNL3) and response to interferon‐alpha treatment in myeloproliferative neoplasms

In myeloproliferative neoplasms (MPN), interferon‐alpha (IFN‐α) is an effective treatment with disease‐modifying properties but currently with no clear predictors of treatment outcome. Recent genomewide association studies in chronic hepatitis C have found a strong influence of genetic polymorphism near the IL28B (IFNL3) gene in response to IFN‐α treatment. In this study, we sought to evaluate the prognostic impact of IL28B rs12979860, rs8099917, and rs12980275 on IFN‐α treatment response in myeloproliferative neoplasms.

[1]  R. Greil,et al.  Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b , 2015, American journal of hematology.

[2]  E. Ejerblad,et al.  A Retrospective Cohort Study of Interferon-α Therapy in Myeloproliferative Neoplasms; Adverse Events, Thromboembolic Incidence and Causes of Termination of Therapy , 2014 .

[3]  T. Hassanein,et al.  A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. , 2014, Journal of hepatology.

[4]  J. Hiscott,et al.  Type I and type III interferon‐induced immune response: It's a matter of kinetics and magnitude , 2014, Hepatology.

[5]  L. Gong,et al.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens , 2014, Clinical pharmacology and therapy.

[6]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[7]  G. Superti-Furga,et al.  Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.

[8]  Francisco Cervantes,et al.  Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. , 2013, Blood.

[9]  O. Abdel-Wahab,et al.  Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. , 2013, Blood.

[10]  A. Gamero,et al.  Interferons as inducers of apoptosis in malignant cells. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[11]  R. Tiu,et al.  Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms. , 2013, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[12]  Kui Li,et al.  Human type 2 myeloid dendritic cells produce interferon-λ and amplify interferon-α in response to hepatitis C virus infection. , 2013, Gastroenterology.

[13]  R. Silver,et al.  Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis , 2013, Expert review of hematology.

[14]  David R Booth,et al.  Pharmacogenomics of hepatitis C infections: personalizing therapy , 2012, Genome Medicine.

[15]  T. Barbui,et al.  Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients , 2012, Haematologica.

[16]  A. Lewis-Antes,et al.  Type III IFNs Are Produced by and Stimulate Human Plasmacytoid Dendritic Cells , 2012, The Journal of Immunology.

[17]  P. Johansson,et al.  Influence of interferon-α treatment outcome in polycythemia vera and essential thrombocythemia by genetic polymorphism in IL28B , 2012 .

[18]  J. Darnell,et al.  The JAK-STAT pathway at twenty. , 2012, Immunity.

[19]  A. Lasfar,et al.  Interferon Lambda: A New Sword in Cancer Immunotherapy , 2011, Clinical & developmental immunology.

[20]  R. Silver,et al.  Recombinant interferon-α may retard progression of early primary myelofibrosis: a preliminary report. , 2011, Blood.

[21]  H. Gisslinger,et al.  Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. , 2011, Blood.

[22]  R. Hoffman,et al.  The renaissance of interferon therapy for the treatment of myeloid malignancies. , 2011, Blood.

[23]  M. Griesshammer,et al.  Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  K. Shianna,et al.  Hepatitis C pharmacogenetics: State of the art in 2010 , 2011, Hepatology.

[25]  S. Kotenko,et al.  Interferon-lambda: a new addition to an old family. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[26]  M. Shiffman,et al.  Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection , 2010, Hepatology.

[27]  Sven Bergmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[28]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[29]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[30]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[31]  M. Griesshammer,et al.  Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. , 2009, Blood.

[32]  S. Chevret,et al.  Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.

[33]  S. Schwartz.  Myeloproliferative Disorders , 1975, Annals of surgery.

[34]  A. Lewis-Antes,et al.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. , 2003, Nature immunology.

[35]  Scott R. Presnell,et al.  IL-28, IL-29 and their class II cytokine receptor IL-28R , 2002, Nature Immunology.